Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma by Miguel, Antonio et al.
© 2017 Miguel et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
OncoTargets and Therapy 2017:10 503–514
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
503
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S104393
Silencing of Foxp3 enhances the antitumor efficacy 
of GM-CSF genetically modified tumor cell 
vaccine against B16 melanoma
antonio Miguel1
luis sendra1
Verónica noé2
carles J ciudad2
Francisco Dasí3,4
David hervas5
María José herrero1,6
salvador F aliño1,7
1Department of Pharmacology, Faculty 
of Medicine, University of Valencia, 
2Department of Biochemistry 
and Molecular Biology, Faculty of 
Pharmacy, University of Barcelona, 
3research University hospital of 
Valencia, incliVa health research 
institute, 4Department of Physiology, 
Faculty of Medicine, University of 
Valencia Foundation, 5Biostatistics 
Unit, 6Pharmacogenetics Unit, 
instituto de investigación sanitaria la 
Fe (iis la Fe), 7clinical Pharmacology 
Unit, acM hospital Universitario y 
Politécnico la Fe, Valencia, spain
Abstract: The antitumor response after therapeutic vaccination has a limited effect and seems 
to be related to the presence of T regulatory cells (Treg), which express the immunoregula-
tory molecules CTLA4 and Foxp3. The blockage of CTLA4 using antibodies has shown an 
effective antitumor response conducing to the approval of the human anti-CTLA4 antibody 
ipilimumab by the US Food and Drug Administration. On the other hand, Foxp3 is crucial for 
Treg development. For this reason, it is an attractive target for cancer treatment. This study aims 
to evaluate whether combining therapeutic vaccination with CTLA4 or Foxp3 gene silencing 
enhances the antitumor response. First, the “in vitro” cell entrance and gene silencing efficacy 
of two tools, 2′-O-methyl phosphorotioate-modified oligonucleotides (2′-OMe-PS-ASOs) and 
polypurine reverse Hoogsteen hairpins (PPRHs), were evaluated in EL4 cells and cultured 
primary lymphocytes. Following B16 tumor transplant, C57BL6 mice were vaccinated with 
irradiated B16 tumor cells engineered to produce granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and were intraperitoneally treated with CTLA4 and Foxp3 2′-OMe-PS-ASO 
before and after vaccination. Tumor growth, mice survival, and CTLA4 and Foxp3 expression 
in blood cells were measured. The following results were obtained: 1) only 2′-OMe-PS-ASO 
reached gene silencing efficacy “in vitro”; 2) an improved survival effect was achieved com-
bining both therapeutic vaccine and Foxp3 antisense or CTLA4 antisense oligonucleotides 
(50% and 20%, respectively); 3) The blood CD4+CD25+Foxp3+ (Treg) and CD4+CTLA4+ cell 
counts were higher in mice that developed tumor on the day of sacrifice. Our data showed that 
tumor cell vaccine combined with Foxp3 or CTLA4 gene silencing can increase the efficacy 
of therapeutic antitumor vaccination.
Keywords: gene silencing, antitumor vaccine, Treg, antisense oligonucleotide, cancer 
immunotherapy
Introduction
Cell vaccines genetically modified to produce proinflammatory cytokines have 
been shown to be effective in several types of cancer.1–10 One of the most success-
ful vaccination approaches in experimental models involves the use of preventive 
granulocyte-macrophage colony-stimulating factor (GM-CSF)-engineered tumor 
cell vaccines,8–10 achieving 100% survival among mice bearing B16 melanoma 
xenografts. However, in the therapeutic setting, such vaccines failed to improve 
overall survival, though they delayed tumor growth and prolonged animal lifetime.9–12 
It is currently accepted that failure of the antitumor response in the therapeutic 
setting could be due to negative immunoregulatory action mediated by regulatory 
T cells (Treg), which express CTLA4 and Foxp3. CTLA4 is a coinhibitory molecule 
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that binds B7 molecules with more affinity than CD28 
coactivator. The interaction of CTLA4 with B7 molecule 
induces downregulatory signals,13,14 and accordingly, anti-
CTLA4 antibodies have been shown to induce effective 
antitumor responses in clinical trials,15,16 leading to their 
approval by the US Food and Drug Administration (FDA) 
for treating advanced melanoma. Since antibodies can only 
block surface molecules and have very limited intracel-
lular access, the use of gene silencing strategies to block 
the expression of intracellular molecules such as nuclear 
transcription factor Foxp3 could be an interesting treat-
ment approach, since Foxp3 plays an important role in Treg 
cell (CD4+CD25+Foxp3+) development and function.17,18 
Recently, a study in a model of murine melanoma has shown 
that gene silencing of Foxp3 in B16 tumor cells, using an 
siRNA plasmid, delays tumor growth and modifies the tumor 
immunosuppressive environment.19
The aim of the present study was to evaluate the pos-
sible synergistic antitumor effect using Foxp3 or CTLA4 
gene silencing treatment before therapeutic vaccination, 
employing GM-CSF-engineered tumor cells. For gene 
silencing, we used two nuclease resistant oligonucleotides: 
2′-O-methylphosphorotioate-modified oligonucleotides 
(2′-OMe-PS-ASOs) and polypurine reverse Hoogsteen 
hairpins (PPRHs), which are DNA hairpins formed by two 
antiparallel polypurine chains joined by reverse Hoogsteen 
bonds. Although both antisense oligonucleotides (ASOs) 
and PPRHs have yielded promising results in preclinical 
studies,20–23 only ASOs have demonstrated clinical interest. 
Our “in vitro” studies indicate that only ASOs could be used 
for “in vivo” experiments, since naked PPRHs showed low 
cell entrance and gene silencing efficacy. Using the best 
ASO found in our “in vitro” studies, we conducted “in vivo” 
experiments that revealed a synergistic antitumor effect 
(50% mice survival) employing Foxp3 ASO plus GM-CSF 
cell vaccine, thus suggesting the potential interest of gene 
silencing strategies in cancer treatment.
Materials and methods
nucleic acids
The plasmid employed was p2F GM-CSF (Figure 1) derived 
from the pVITRO2 base plasmid (InvivoGen, San Diego, 
CA, USA), which carries the murine gm-csf gene under the 
control of the ferritin promoter.
To design the PPRHs, we used the Triplex-Forming 
Oligonucleotide Target Sequence Search tool from the MD 
Anderson Cancer Center (Houston, TX, USA) website. The 
ASOs were directed against the same target sequences as the 
PPRHs, and were used with the 2′-O-methyl phosphorotioate 
modification (2′-OMe-PS-ASO). ASOs and PPRHs were 
purified by high-performance liquid chromatography. PPRHs 
were purchased from Thermo Fisher Scientific (Waltham, MA, 
USA) and 2′-OMe-PS-ASOs were purchased from biomers.
net GmbH (Ulm, Germany). The sequences corresponding 
to the designed ASOs and PPRHs are given in Table 1. The 
designed ASO and PPRH controls correspond to oligonucle-
otides with average sizes equivalent to those of ASO and 
PPRH used in this study and with scrambled sequence.
animals and cells
Male C57BL/6 mice (8–10 weeks old) were kept under standard 
laboratory conditions. The maximum number of mice housed 
per cage was ten. All the mice used in this work were labeled 
in the ears for identification purposes. The experimental project 
(A1319118959093) was approved by the Biological Research 
Committee of the University of Valencia (Valencia, Spain) and 
followed European directive 63/2010 and Spanish directive 
RD 53/2013 for animal care. B16 murine melanoma cells were 
used for the vaccination experiment in syngeneic C57BL/6 
mice. Tumor cells were transfected using p2F GM-CSF/PEI 
25 kDa (polyethyleneimine; Sigma-Aldrich Co., St Louis, 
MO, USA) polyplexes (DNA:PEI, 1:1.41 w/w) with 20 μg/mL 
of plasmids, as previously described,24,25 and were irradiated 
after 24 hours with 150 Gy. Then, cells were frozen and stored 
at −80°C until further use. Murine lymphoblastic lymphoma 
EL4.BU.OU6 cells and mouse lymphocytes in primary culture 
were also used for “in vitro” gene silencing experiments. EL4 
cells were used because they express the target genes. Murine 
melanoma B16 cells and thymoma murine EL4.BU.OU6 cell 
line were purchased from European Collection of Cell Cultures 
(Salisbury, UK), and lymphocytes were obtained from mouse 
blood (50 μL/mouse) by saphen vein puncture through gradi-
ent centrifugation using Ficoll-Paque Plus® (GE Healthcare 
Bio-Sciences Corp., Piscataway, NJ, USA).
Figure 1 p2F gM-csF plasmid schema.
Abbreviations: hygro r gene, hygromycin resistance gene; cMV enh, cytomegalovirus enhancer; Ferl prom, light chain ferritin promoter; eF1, elongation factor-1; 
mgM-csF, mouse granulocyte-macrophage colony-stimulating factor gene; Ori pMB1, replication origin from plasmid pMB1; sV40 enh, simian vacuolating virus 40 enhancer.
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in vitro experiments
EL4 cells and primary cultured mouse lymphocytes 
(1×106 cells) were incubated in the presence of different con-
centrations of 2′-OMe-PS-ASO-control and PPRH-control 
labeled with FAM at different time points. Then the cells 
were analyzed by flow cytometry (FACS Verse [BD Bio-
sciences, San Jose, CA, USA] and AMNIS ImageStreamX 
Mark II [EMD Millipore, Billerica, MA, USA] to determine 
whether 2′-OMe-PS-ASO-FAM and PPRH-FAM) entered 
the cell or remained attached to the membrane. The naked 
ASO-control and PPRH-control were added to culture 
medium without any carrier. They probably enter into the 
cell through a concentration-dependent mechanism, since 
energy-dependent transport has not been reported to the best 
of our knowledge.
EL4 and lymphocytes were incubated in the presence 
of 2′-OMe-PS-ASO and PPRH for different time points 
(1–48 hours) and concentrations (1 nM–1 mM). Then, RNA 
was extracted and the mRNA levels of CTLA4 and Foxp3 
were evaluated by quantitative reverse transcription poly-
merase chain reaction (RT-PCR). Since mRNA expression 
in untreated cells and in cells treated with PPRH-control 
and ASO-control was the same, these were considered as 
reference value (100%) to calculate the silencing efficiency 
of the specific ASO and PPRH, respectively.Cellular toxicity 
of oligonucleotides was evaluated using the calcein-AM test 
(Thermo Fisher Scientific).
Plasma concentrations of 2′-OMe-Ps-
asO and PPrh in mice
2′-OMe-PS-ASO (87 μg/mouse) and PPRH (175 μg/mouse) 
labeled with FAM were injected intraperitoneally into 
C57BL/6 mice (n=3), and their plasma concentrations at 
different time points were evaluated. Blood samples (50 μL 
from saphenous vein) were obtained 5, 15, and 30 minutes, 
and 1, 2, 4, 6, 12, 24, and 48 hours after injection. Fluores-
cence in blood was measured with a fluorimeter (CytoFluor 
2350; EMD Millipore), and their concentrations were deter-
mined from the equation of the curve.
Therapeutic vaccines plus gene silencing
B16 cells genetically modified and irradiated as explained in 
“Animals and cells” section were thawed, washed, counted 
in a Bauer chamber, and resuspended (2×106 cells/mouse) 
in 200 μL Dulbecco’s Modified Eagle’s Medium (DMEM), 
and were subcutaneously (in the back) injected on days 3, 
10, and 17 after tumor subcutaneous injection (day 0, 2×104 
wild-type nonirradiated B16 cells) in the left leg. In addition, 
2′-OMe-PS-ASO-control, 2′-OMe-PS-ASO anti-CTLA4, 
and/or 2′-OMe-PS-ASO anti-Foxp3 were injected on 
days 2, 4, 7, and 9. The blood samples (50 μL) were taken 
on days −7, 2, 4, 8, 11, 15, 18, and 21 by puncture of saphen 
vein (maximum 200 μL/mouse every 21 days). CTLA4 
and Foxp3 mRNA expression of genes in peripheral blood 
lymphocytes was studied.
Table 1 sequence and location of all 2′-OMe-Ps-asOs and PPrhs tested
Name Location (target) Sequence (5′→3′)
CTLA4
asO 1 intron 3 (coding) ggaggagTaggaagagTaag
asO 2 exon 1 (coding) gaagagTgagcaggg
asO 9 intron 3 (template) gaaTgagaaggaTgaggagg
asO 10 exon 1 (template) gggacgagTgagaag
PPrh 1 intron 3 (coding) gaaagagaaggaagaggaggTTTTTggaggagaaggaagagaaag
PPrh 2 exon 1 (coding) gggaagagagagaagTTTTTgaagagagagaaggg
PPrh 5 intron 3 (template) gggaaaggaaggaagaggaaTTTTTaaggagaaggaaggaaaggg
PPrh 6 exon 1 (template) agaggagagaggaagTTTTTgaaggagagaggaga
Foxp3
asO 3 exon 13 (coding) aggagaTagagTggagggg
asO 4 intron 1 (coding) gggggaagcacggaaggg
asO 11 exon 13 (template) ggggaggTgagaTagagga
asO 12 intron 1 (template) gggaaggcacgaaggggg
PPrh 3 exon 13 (coding) ggggaggagagaaagaggaTTTTTaggagaaagagaggagggg
PPrh 4 intron 1 (coding) gggaaggaaagaagggggTTTTTgggggaagaaaggaaggg
PPrh 8 exon 13 (template) gagggaagagagagaggagagTTTTTgagaggagagagagaagggag
PPrh 9 intron 1 (template) aagaggggaagaaggggTTTTTggggaagaaggggagaa
Controls
asOcont scrambled aggaggacaggagagTaga
PPrhcont scrambled aggaggaaaggagagaagaTTTTTagaagagaggaaaggagga
Abbreviations: asO, antisense oligonucleotide; PPrh, polypurine reverse hoogsteen hairpin; cont, control; asOcont, asO scrambled sequence; PPrhcont, PPrh 
scrambled sequence.
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The vaccination groups were as follows: a) control, 
DMEM only; b) Vac+ASOcont, transfected irradiated B16 
cells vaccine and 2′-OMe-PS-ASO-control administered; 
c) Vac+ASOctla4, transfected irradiated B16 cells vac-
cine and 2′-OMe-PS-ASO anti-CTLA4 administered; and 
d) Vac+ASOfoxp3, transfected irradiated B16 cells vaccine 
and 2′-OMe-PS-ASO anti-Foxp3 (n=19, n=5 per group, 
except group “d”, where n=4, due to failure in the first 
2′-OMe-PS-ASO administration). Mice were assigned to 
groups on a random basis.
To determine the presence of depigmentation or diarrhea 
as possible adverse effects, animals were visually monitored 
and weighed three times a week. Tumor growth in mice was 
also visually monitored and measured with a caliper in two 
dimensions: A (long diameter) and B (short diameter). Tumor 
volume was calculated with the formula: V = (A × B2)/2. 
When tumor volume reached 1,500 mm3, animals were 
euthanized, and “date of death” was recorded to construct 
survival curves. Lungs were extracted to study the possible 
presence of metastases. Furthermore, blood was extracted 
through the cava vein to conduct a study of Treg and CTLA4 
lymphocytes in blood. Mice were anesthetized with isoflurane 
(IsoFlo; Esteve, Barcelona, Spain) before euthanasia and 
before tumor vaccine and tumor injection.
characterization of Treg and 
cD4+cTla4+ cells by flow cytometry
Lymphocytes were separated from blood using Ficoll-Paque 
Plus (GE Healthcare Bio-Sciences Corp.). The lympho-
cyte sample of each group was divided into two parts: one 
for CD4+CTLA4+ staining and the other for dyeing Treg 
(CD4+CD25+Foxp3) lymphocytes. To determine CD4+ 
lymphocytes, we used goat fluorescein isothiocyanate 
(FITC)-labeled anti-mouse CD4, and to determine CTLA4 
lymphocytes, we used goat phycoerythrin (PE)-labeled anti-
mouse CTLA4 – both from eBioscience (Santa Clara, CA, 
USA). To determine the number of Treg lymphocytes, we 
used Mouse Regulatory T Cell Staining Kit # 2 (eBioscience). 
The samples were analyzed by flow cytometry (FACS Verse; 
BD Biosciences).
Quantitative rT-Pcr
To quantify the mRNA of CTLA4 and Foxp3, RNA from 
cultured cells or peripheral blood was obtained with a com-
mercial kit (RNeasy Mini Kit [Quiagen NV, Venlo, the 
Netherlands] or NuceloSpin® Blood RNA [Machery-Nagel 
Inc., Dueren Germany], respectively). RNA was converted 
into cDNA by retrotranscription. RT and quantitative PCR 
allowed quantification of the number of copies of mRNA 
using a 7900HT Fast Real-Time PCR System (Thermo Fisher 
Scientific). The number of mRNA copies was obtained from 
dose–response curves of Ct versus DNA copy number. To 
amplify DNA of CTLA4 and Foxp3, TaqMan Copy Number 
Assays (Thermo Fisher Scientific) were used.
statistical methods
Data were summarized as the mean and standard deviation in 
the case of continuous variables and as relative and absolute 
frequencies in the case of categorical variables. Multiple 
linear regression was used for assessing differences in tumor 
growth among groups and for comparing mRNA expres-
sion levels. Final survival differences between groups were 
assessed using L2-penalized logistic regression (ridge logistic 
regression), and survival curves were compared with a Cox 
regression model. Lymphocyte populations were compared 
using a beta-regression model. All statistical analyses were 
performed using R software 3.2.1.
Results
2′-OMe-Ps-asO penetrates cells better 
than PPrh
Mouse peripheral blood lymphocytes and EL4 cells were 
incubated with PPRH-FAM or 2′-OMe-PS-ASO-FAM for 
24 hours, and the percentage of labeled cells was analyzed 
by flow cytometry (Figure 2A and B). A higher concentration 
of PPRH than of 2′-OMe-PS-ASO was needed to achieve 
the same percentage of labeled EL4 cells and lymphocytes 
(200-fold and tenfold, respectively). Likewise, 100-fold and 
fivefold higher concentrations of 2′-OMe-PS-ASO and PPRH 
in lymphocytes versus EL4 cells, respectively, were required 
to achieve the same percentage of labeled cells.
Figure 2C provides a representative image of EL4 cells 
labeled with 2′-OMe-PS-ASO-FAM and PPRH-FAM (green 
fluorescence), showing that the molecules are located within 
the cell and are not absorbed in the surface membrane. The 
AMNIS algorithm for calculating the percentage of internal-
ization of 2′-OMe-PS-ASO-FAM and PPRH-FAM indicated 
a penetration of 95%–99%. We thus confirmed that 2′-OMe-
PS-ASO and PPRH were effectively entering the cells.
in vitro gene silencing with 2′-OMe-Ps-
asO is more effective than PPrh
The “in vitro” gene silencing efficacy of the designed PPRH 
and 2′-OMe-PS-ASO was evaluated in EL4 cells. We used 
cells incubated in the absence of 2′-OMe-PS-ASO or PPRH 
as controls. The groups treated with ASO-control and 
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PPRH-control obtained the same level of mRNA expression 
of target genes as the nontreated cells; we considered this 
mRNA expression to represent 100% expression in order to 
establish comparisons with the other groups. The results of 
gene expression inhibition are represented in Figure 3A–D. 
2′-OMe-PS-ASO achieved the best results at a concentration 
of 1 μM, determining the levels of mRNA 48 hours post-
transfection. The best results were achieved with 2′-OMe-PS-
ASO 2 and 2′-OMe-PS-ASO 4, inhibiting mRNA expression 
of CTLA4 and Foxp3 by up to 52% and 50%, respectively. 
In contrast, the “in vitro” efficacy of PPRH was always lower 
than 13%. The data showed that higher concentrations of 
PPRH than of 2′-OMe-PS-ASO were necessary to silence 
a gene. Cell viability in all cases was greater than 70% 
(Figure 3E and F), indicating that neither ASO nor PPRH 
induced relevant cytotoxicity “in vitro” 48 hours after they 
were added to the cells.
Plasmatic concentrations of 2′-OMe-Ps-
asO and PPrh
The results of the study of the plasmatic concentrations 
of 2′-OMe-PS-ASO and PPRH after peritoneal injection 
in mice are shown in Figure 4. A first absorption step of 
2′-OMe-PS-ASO was observed in which the maximum 
concentration was reached in blood within 30 minutes, and 
from this moment onward a sharp drop in blood concentra-
tion was recorded (rapid kinetic disposition), followed by a 
slower fall (slow kinetic disposition) – becoming negligible 
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Figure 2 Identification of EL4 ASO-FAM- and PPRH-FAM-positive lymphocytes and EL4 cells.
Notes: el4 cells or mouse lymphocytes extracted from peripheral blood were incubated in the presence of different concentrations of asO-FaM (A) and PPrh-FaM (B) 
during 24 hours and were then analyzed by flow cytometry. The percentages of ASO-FAM-positive and PPRH-FAM-positive cells are represented in the figures. (C) intracellular 
presence of ASO and PPRH in EL4 cells is shown. Image was taken with the AMNIS flow cytometer, where it can be observed that ASO-FAM and PPRH-FAM (green) are 
located within the cell. el4 cells were incubated with asO-FaM and PPrh-FaM (green) and anti-cD45 (orange).
Abbreviations: ASO, antisense oligonucleotide; PPRH, polypurine reverse Hoogsteen hairpin; FAM, 6-Carboxyfluorescein; PE, phycoerythrin.
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at 4 hours after injection. We observed similar results with 
PPRH, though the fall in concentration in the rapid dispo-
sition phase was more pronounced – reaching low blood 
concentrations sooner. With these data, we calculated that 
the amounts of 2′-OMe-PS-ASO and PPRH that would be 
required to achieve potential therapeutic concentrations in 
blood, according to the “in vitro” silencing studies, would 
be 500 μg per mouse and 19.5 mg per mouse, respectively. 
Due to the high amounts required for PPRH (without vector), 
they were not included in the “in vivo” experiments.
Tumor cell vaccine plus cTla4/Foxp3 
gene silencing delays tumor growth
Based on aforementioned results, we examined whether 
the combination of therapeutic cell vaccine with gm-csf 
genetically modified cells and CTLA4/Foxp3 gene silencing 
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Figure 3 in vitro effect of asO and PPrh in cTla4 and Foxp3 expression and cytotoxicity.
Notes: (A–D) cTla4 and Foxp3 in vitro gene silencing is shown. el4 cells were incubated in the presence of different concentrations of asO or PPrh versus cla4 and 
Foxp3 genes for 1 hour, and RNA extraction was performed at 24 hours or 48 hours. The figures show the percentage inhibition of mRNA of each gene versus control 
(no asO or PPrh) (n=2). (E, F) cytotoxicity of asO and PPrh is shown. el4 cells were incubated for 24 hours or 48 hours in the presence of anti-cTla4 asO or anti-
Foxp3 asO (1 μM), or for 48 hours in the presence of PPrh (50 μM). calcein-aM was added, and cell viability was determined by testing calcein ester metabolism. Figures 
represent the percentage viability of cells incubated with asO and PPrh (n=2).
Abbreviations: asO, antisense oligonucleotide; PPrh, polypurine reverse hoogsteen hairpin.
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promoted tumor rejection in mice. We selected 2′-OMe-PS-
ASO 2 and 2′-OMe-PS-ASO 4 to silence CTLA4 gene and 
Foxp3 gene, respectively. The results of tumor volumes 
obtained this experiment are shown in Figure 5A–D. Only 
mice that developed tumor are represented in these figures; 
the rest of mice did not develop tumor. The tumor began to 
be visible from day 15 onward. Tumor growth was slower 
in mice of the Vac+ASOctla4 and Vac+ASOfoxp3 groups. 
Mice belonging to the Vac+ASOfoxp3 group showed delayed 
tumor growth more than any other group but no significant 
differences were observed between the groups.
Tumor cell vaccine plus cTla4/Foxp3 
gene silencing improves survival in mice
The survival curves of the different treated groups are 
represented in Figure 5E. Vac+ASOfoxp3 was the the best 
performing group, achieving 50% (2/4) survival (P=0.04). 
Both the Vac+ASOctla4 and Vac+ASOcont groups achieved 
20% (1/5) overall survival.
There were no cases of lung metastases that were 
detected, and no cases of animal depigmentation or diarrhea 
were observed.
early cTla4 and Foxp3 mrna 
expression is related to tumor 
development
CTLA4 and Foxp3 gene expression was studied in the vac-
cinated mice. With the aim of obtaining enough blood to 
guarantee effective mRNA extraction, all blood samples 
were pooled in only two different groups according to the 
success of the response against the tumor: “nonresponders” 
(tumor development, n=15) or “responders” (no tumor 
development, n=4). Blood samples from days −7 and 2 
(before any treatment) were pooled for this experiment, as 
they were expected to yield homogeneous results, since they 
all belonged to syngeneic mice without any pretreatment. 
Figure 6A and B represents the mRNA copy number of these 
genes transcribed in the nonvaccinated control group (only 
tumor was implanted).
Figure 6A shows a peak of CTLA4 mRNA expression on 
day 4 (12,000 mRNA copies of CTLA4/100 ng total RNA) 
and another lower peak on day 11. On the remaining days, 
mRNA production was more similar to day −7 (2,000 CTLA4 
mRNA copies/100 ng total RNA). Figure 6B shows a peak 
of Foxp3 mRNA expression on days 2 and 4 (1,900 Foxp3 
mRNA copies/100 ng total RNA) and another lower peak 
on day 11. On the remaining days, Foxp3 mRNA expression 
was more similar to day −7 (700 Foxp3 mRNA copies/100 ng 
total RNA).
Figure 6C and D represents the difference in percentage 
of CTLA4 and Foxp3 mRNA copies with respect to day −7 
in the responder versus the nonresponder group. CTLA4 and 
Foxp3 mRNA expression was lower in the responder group 
than in the nonresponder group on day 4 and higher on day 11 
(P=0.0032 in CTLA4 and P=0.0088 in Foxp3).
Blood cD4+cTla4+ and 
cD4+cD25+Foxp3+ cells are more 
numerous in nonresponders than in 
responders
With the aim of determining whether there were differences 
between the nonresponder and responder groups in the Treg 
(CD4+CD25+Foxp3+) and CD4+CTLA4+ lymphocyte popula-
tions, blood samples from mice included in the study and a 
new group of mice without tumor implantation (n=5) were 
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Figure 4 Plasma concentrations of asO and PPrh.
Notes: scrambled asO (87 μg/mouse) or PPrh (175 μg/mouse) marked with the fluorochrome FAM was administered intraperitoneally to C57BL/6 mice, and blood 
samples were taken at different time points (5, 15, 30, 60, 120, 240, and 480 minutes). Fluorescence of each blood sample was measured, and asO-FaM and PPrh-FaM 
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analyzed by flow cytometry. The results are represented in 
Figure 7. The responder group had a lower percentage of 
CD4+CTLA4+ and CD4+CD25+Foxp3+ lymphocytes than 
the nonresponder group and the nonvaccinated control group 
(P=0.0001 and P=0.011 in CD4+CD25+Foxp3+).
Discussion and conclusion
In this study, we evaluated the potential effects of engineered 
antitumor cell vaccine combined with gene silencing strate-
gies. To this effect, we used 2′-OMe-PS-ASOs against Foxp3 
and CTLA4 that are involved in Treg immunosuppressive 
effects. After tumor implantation in mice, we achieved 50% 
and 20% survival employing an antitumor vaccine consisting 
of B16 GM-CSF genetically modified cells combined with 
anti-Foxp3 and anti-CTLA4 2′-OMe-PS-ASO, respectively. 
In contrast, no survival was observed in the control group. 
These results are in agreement with an “in vitro” study in 
which Foxp3 gene silencing achieved a decrease in CTLA4 
expression and an increase in antitumor immune response.26
For the “in vivo” experiment in this study, we used 
2′-OMe-PS-ASO because we found the latter to be more 
effective than PPRH for CTLA4 and Foxp3 gene silencing 
“in vitro”, due to difficulties in the penetration of PPRHs 
into the cells without a vector. In other studies, PPRHs have 
yielded good results when used with a vector in both “in vitro” 
and “in vivo” models.20–23 These results, considered glob-
ally, suggest that PPRH could be useful only with a carrier. 
Although 2′-OMe-PS-ASO and PPRH showed comparable 
blood concentration levels after peritoneal injection, PPRH 
performed much poorer than 2′-OMe-PS-ASO on cells 
in vitro. This could be due to the fact that PPRHs are larger 
and cell membrane barriers offer more strict size limitations 
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Figure 6 cTla4 and Foxp3 expression after tumor implanted.
Notes: (A, B) cTla4 and Foxp3 expression after tumor implanted in nonvaccinated mice. Figures represent mrna copy number of cTla4 (A) and Foxp3 (B)/100 ng total 
rna on different days after tumor implantation (day 0) in the nonvaccinated control group. animals of this group were administered DMeM after tumor injection (n=5). 
(C, D) CTLA4 and Foxp3 mRNA expression in the responder and nonresponder groups. The figure represents the difference in percentage mRNA copies of CTLA4 (C) 
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Abbreviations: DMEM, Dulbecco’s Modified Eagle’s Medium; Cont, control.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
1.
11
6.
16
8.
92
 o
n 
03
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
512
Miguel et al
$ 




&'&7/$
&
7/$
 LQ
&'

FHOO
V








%
&
'
 )R
[S
 LQ
&'
FHO
OV
&'&')R[S
&RQWQRQYDFFLQDWHG 1RQUHVSRQGHUV 5HVSRQGHUV
Figure 7 comparison of cTla4 and Foxp3 lymphocyte populations in the different vaccinated groups.
Notes: (A) represents the percentage cTla4+ cells from cD4 cells and (B) represents cD25+Foxp3+ from cD4 cells in the nonresponder group (mean), responder 
group, and control-nonvaccinated group. Statistically significant differences of each group versus the responder group were calculated using beta-regression, *P=0.011 and 
***P=0.0088.
than absorption by blood from a peritoneal injection. The dose 
of 2′-OMe-PS-ASO used in our study (500 μg/dose/mouse) 
is consistent with the doses previously described in the 
literature.27–30 There are multiple clinical trials with ASOs,31–33 
and two of them – fomivirsen and mipomersen – were 
approved by the FDA in 1998 and 2013, respectively. Paren-
teral administration of several ASOs has shown their clinical 
efficacy and was found to be well tolerated.
We observed a peak in CTLA4 and Foxp3 mRNA on 
days 2–4 and 11 after tumor implantation. The initial increase 
in Foxp3 mRNA (day 2) after tumor implantation seemed 
faster than that of CTLA4 mRNA (day 4). This could be 
due, at least in part, to the fact that CTLA4 gene expression 
is upregulated by Foxp3.34–39 Furthermore, we observed that, 
on day 4, CTLA4 and Foxp3 gene expression was greater 
in the mice that did not respond positively to the treatment 
than in those that responded positively. We think that initial 
increase of FoxP3 and CTLA4 mRNAs after tumor injection 
is related to the tumor tolerance onset and tumor progression. 
Thus, avoiding this early (days 2–4) increase in Foxp3 and 
CTLA4 expression could be crucial to avoid the tumor devel-
opment. These results suggest that the early expression (day 4 
after tumor implantation) of CTLA4 and Foxp3 is related to 
immunosuppression and tumor development. However, on 
day 11, lower Foxp3 and CTLA4 expression was observed 
in the mice that did not respond to the treatment. We do not 
know the reasons for this effect, though it could be due to the 
expression of CTLA4 in CD4-activated lymphocytes. On the 
other hand, since it has been shown that TCR stimulation 
can induce Foxp3 expression in FoxP3−CD4+ T cells with-
out conferring suppressive activity,40–45 our results support 
the idea that the expression of CTLA4 and Foxp3 observed 
at day 11 might not be related to the presence of Treg. 
Thus, Foxp3 seems to be necessary but not sufficient for 
Treg development.
In our experiments, the group vaccinated and treated with 
anti-CTLA4 2′-OMe-PS-ASO did not obtain the success 
recorded in other previous studies using GM-CSF producer 
B16 cells and anti-CTLA4 antibodies.46 This probably could 
be due to the different mechanisms of action of these blocking 
strategies. Recently, a study showed Treg depletion observed 
in the tumor infiltrate after anti-CTLA4 therapy to be mainly 
mediated by antibody-dependent cell cytotoxicity.47 In our 
study, treatment with anti-CTLA4 2′-OMe-PS-ASO blocked 
CTLA4 expression, but this did not deplete Treg cells – thus 
indicating that they can also mediate immunosuppression 
through other mechanisms alternative to CTLA4.48
The successful outcomes achieved in the group of animals 
vaccinated and treated with anti-Foxp3 2′-OMe-PS-ASO 
confirm Foxp3 as a key point in the immunosuppressive 
response mediated by Treg cells. Furthermore, these results 
suggest that Foxp3 gene silencing is a promising strategy in 
cancer treatment. Although we did not study the effect of 
ASOs used in our study on Foxp3 silencing in melanoma 
cells, other authors have shown that its reduced expression, 
employing a small interference Foxp3 plasmid transfection 
procedure, can delay tumor growth.19 According to these 
results, the systemic administration of ASOs could offer 
synergistic antitumor effects by acting on both lymphocytes 
and melanoma cells. In addition, a previous study using len-
tiviral vector codifying for shRNA showed Foxp3 to achieve 
tumor growth delay and prolong animal survival in a murine 
leukemia model.49 In our study, we improved those results, 
achieving up to 50% animal survival in the group vaccinated 
and treated with anti-Foxp3 2′-OMe-PS-ASO. Furthermore, 
we did not observe the characteristic adverse effects of 
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treatment with anti-CTLA4 antibodies, ie, depigmentation, 
diarrhea, or weight loss, described in other studies.50,51
On the other hand, we found an increase in CD4+CTLA4+ 
lymphocytes and classical Treg cells (CD4+CD25+Foxp3+) 
in animals that developed tumor, compared to those that did 
not develop tumor.
Our data support the notion that the lack of efficacy 
observed in therapeutic vaccinations is mainly associated to 
the expression of certain immunosuppressive genes.52,53 Also, 
we have found that combining gene silencing with antitumor 
therapeutic vaccination mediates synergistic effects, thus 
suggesting Treg response modulation by gene silencing to 
be an attractive alternative to the use of antibodies. Finally, 
although the silencing of Foxp3 is presented as a candidate 
of great interest in cancer treatment, new studies to increase 
the efficiency of silencing are needed in order to optimize 
the results obtained in our work.
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